![]() Steven Gillis is a Managing Director with ARCH, joining the firm as a Venture Partner in 2005. Managing Director of ARCH Venture Partners in Chemistry from the University of Texas at Arlington. Crandell was with the specialty chemical and polymer company, Hercules, Inc. Crandell also serves as a Director of the Illinois Venture Capital Association. He is a Director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, Ciespace. He was also responsible for ARCH’s investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. ![]() Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. Crandell is the Co – Founder & Managing Director, ARCH Venture Partners. from the University of Puget Sound with majors in Economics and Biology.Ībout ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.įounder and Managing Director of ARCH Venture Partners from the University of Chicago and a B.S. ![]() He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. His seed and early-stage investments include Illumina (ILMN) Alnylam Pharmaceuticals (ALNY) Juno Therapeutics (JUNO) Unity Biotechnology (UBX) Sienna Biopharmaceuticals (SNNA) Vir Biotechnology, Agios Pharmaceuticals (AGIO) Sage Therapeutics (SAGE) GRAIL, Ikaria Kythera Biopharmaceuticals (KYTH), Receptos (RCPT) Aviron (AVIR) Denali Therapeutics (DNLI) Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot Bluebird Bio (BLUE) R2 Technology XenoPort (XNPT) Caliper Life Sciences (CALP) Trubion Pharmaceuticals (TRBN) Adolor (ADLR) deCODE Genetics Array BioPharma (ARRY) Editas (EDIT), IDUN Pharmaceuticals Hua Medicine Fate Therapeutics (FATE) WuxiNextCODE and Everyday Learning Corporation. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. Co-Founder & Managing Director of ARCH Venture Partners ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |